Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 465 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: venetoclax Clear all
Recruiting Phase 1 Interventional

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

NCT06708897
View directory record Official record
Conditions
CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions
Lonitoclax (ZE50-0134)
Drug
Lead sponsor
Lomond Therapeutics Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

NCT03045328
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Venetoclax
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Duarte, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 25, 2026, 4:41 AM EDT
Active, not recruiting Phase 1 Interventional

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

NCT05053659
View directory record Official record
Conditions
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Loncastuximab tesirine, Venetoclax
Drug
Lead sponsor
Paolo Caimi, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

NCT05379166
View directory record Official record
Conditions
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions
Azacitidine, Quality-of-Life Assessment, Questionnaire Administration, Venetoclax
Drug · Other
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Columbus, Ohio • Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 4 Interventional

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions
Acalabrutinib, Investigator's choice of treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Terminated Phase 1 Interventional

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

NCT04553692
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Interventions
Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 25, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

NCT03226418
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

NCT03319901
View directory record Official record
Conditions
Leukemia
Interventions
Venetoclax, Standard Chemotherapy
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

NCT04493099
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Alvocidib Hydrochloride, Decitabine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 25, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

NCT04487106
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Trametinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 25, 2026, 4:41 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

NCT04274933
View directory record Official record
Conditions
Breast Cancer, Cancer
Interventions
Venetoclax, Capecitabine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 25, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

NCT05155709
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
siremadlin, venetoclax, azacitidine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT05536349
View directory record Official record
Conditions
Leukemia
Interventions
Pirtobrutinib, Obinutuzumab, Venetoclax, Valacyclovir, Allopurinol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Azacitidine, Venetoclax
Drug
Lead sponsor
Joshua Zeidner
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Not listed Phase 1Phase 2 Interventional

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

NCT05503355
View directory record Official record
Conditions
AML, Adult
Interventions
BST-236, venetoclax
Drug
Lead sponsor
BioSight Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

NCT06782542
View directory record Official record
Conditions
Acute Myeloid Leukemia, IDH1 Mutation
Interventions
Olutasidenib, Venetoclax, Azacitidine
Drug
Lead sponsor
Justin Watts, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 1 Interventional

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Interventions
Dasatinib, Methotrexate, Prednisone, Rituximab, Venetoclax, Blinatumomab, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT07437950
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
41
States / cities
Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

NCT04801797
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Daunorubicin, Liposomal daunorubicin and cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Terminated Phase 2 Interventional Results available

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

NCT03969420
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Clovis, California • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 25, 2026, 4:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597
View directory record Official record
Conditions
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Interventions
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, Daratumumab
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 25, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT01671904
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Obinutuzumab, Rituximab, Venetoclax
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 25, 2026, 4:41 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
18
States / cities
Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 4:41 AM EDT